drugset / Trial / NCT06270433
Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of anhedonia in patients with major depression disorder compared to desvenlafaxine succinate sustained-release tablets, to provide evidence-based basis for clinical rational drug use.
Timeline
- Start
- 2024-02-19
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Desvenlafaxine | Other / unclassified | 50 mg | Oral |
| Subject | Toludesvenlafaxine | Small molecule | 80 mg | Oral |
| Subject | Toludesvenlafaxine | Small molecule | 120 mg | Oral |
| Subject | Toludesvenlafaxine | Small molecule | 160 mg | Oral |